The recently announced site closures by Novartis ($NVS) in Switzerland may be an indication that the country's pharmaceutical industry is being forced to move away from mass production. "High quality products that require a lot of research and development will always be made in Switzerland while finished products will be made elsewhere," said Julius Bär economist Janwillem Acket in Le Temps. Story